Hi-Tech Pharmacal Reports an 8% Sales Increase and a 44% EPS Increase for the Third Fiscal Quarter Ended January 31, 2006

Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the quarter and nine months ended January 31, 2006.

Third Quarter Results

For the three months ended January 31, 2006, the Company reported net sales of $22.9 million, an increase of 8% from $21.2 million for the same period last year. Net income increased 52% to $4.9 million from $3.2 million and fully diluted earnings per share rose to $0.36 compared to $0.25 for the same fiscal quarter last year.

During the quarter ended January 31, 2006, net sales of generic pharmaceutical products were $19.2 million, an increase of 10% compared to $17.4 million for the same fiscal 2005 period.

Sales for the Health Care Products division, which markets the Company’s OTC branded products, increased 13% to $3.0 million for the three months ended January 31, 2006 largely due to sales of the recently acquired Zostrix(R) line of products.

Sales of Naprelan(R) totaled $0.7 million, down from $1.1 million in the comparable period the prior year. This is a result of heavier than normal purchases of the 500mg strength at the end of the second quarter in advance of an announced price increase.

Nine Month Results

For the nine months ended January 31, 2006, the Company reported net sales of $59.9 million, an increase of 20% from net sales of $50.0 million for the nine months ended January 31, 2005. Net income increased 46% to $9.4 million or $0.70 per fully diluted share for the nine months ended January 31, 2006 compared to $6.4 million, or $0.49 per share, for the same period ended January 31, 2005.

Generic pharmaceutical product sales were $50.8 million for the nine month period ended January 31, 2006, compared to $41.5 million for the nine months ended January 31, 2005, an increase of 22%. Sales of Naprelan(R) for the nine months were flat at $1.9 million. The Health Care Products division had net sales of $7.2 million and $6.6 million for the nine months ended January 31, 2006 and 2005, respectively, an increase of 9%.

David Seltzer, President and CEO, commented on the results: “We are pleased with the third quarter results. Strong sales of both recently introduced and core generic products helped offset slower demand for our cough and cold products caused by a relatively mild winter season.”

Hi-Tech currently has eleven products awaiting approval at the FDA. These products target brand sales of over $1.5 billion. In addition to these products awaiting approval at the FDA, Hi-Tech has fifteen products in active development targeting brand sales of over $1.0 billion, including sterile ophthalmic products, oral solutions and suspensions and nasal sprays.

The Company’s management reiterates its belief that net sales will grow between 15% and 20% for Fiscal Year 2006. The Company’s ability to meet the forecast depends on such factors as the timing of new product launches, regulatory approvals, competition, legal proceedings and other market conditions.

Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription and OTC products. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company’s Health Care Products Division is a leading developer and marketer of branded prescription and OTC products for the diabetes marketplace.

Forward-looking statements (statements which are not historical facts) in this Press Release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not promises or guarantees and investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, the regulatory environment, including without limitation, the outcome of the SEC staff’s investigation and any conclusions reached by the staff which are adverse to the Company, its officers or directors, reliance on key strategic alliances, availability of raw materials, fluctuations in operating results and other results and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. These statements are based on management’s current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward looking statements which speak only as of the date made. Hi-Tech is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

                            Nine Months              Three Months                     01/31/2006   01/31/2005   01/31/2006   01/31/2005                    ———— ———— ———— ———— Net sales          $59,943,000  $50,043,000  $22,897,000  $21,169,000 Cost of goods sold  26,588,000   22,793,000    9,390,000    9,521,000                     ————————————————— Gross profit        33,355,000   27,250,000   13,507,000   11,648,000                    —————————————————  Selling, general,  administrative  expenses           17,352,000   13,748,000    5,669,000    5,591,000 Research & product  development costs   2,264,000    3,738,000      684,000    1,071,000 Contract research  (income)              (27,000)     (25,000)     (27,000) Interest expense        11,000       19,000        1,000        7,000 Interest (income)  and other          (1,111,000)    (406,000)    (590,000)    (138,000)                    ————————————————— Total               18,489,000   17,074,000    5,737,000    6,531,000                    —————————————————  Income before  income taxes       14,866,000   10,176,000    7,770,000    5,117,000 Provision for  income taxes        5,498,000    3,766,000    2,873,000    1,894,000                     ————————————————— Net income           9,368,000    6,410,000    4,897,000    3,223,000                    —————————————————  Basic net earnings  per common share        $0.79        $0.54        $0.41        $0.27  Diluted net  earnings per  common share            $0.70        $0.49        $0.36        $0.25  Weighted average  shares  outstanding: Basic               11,867,000   11,919,000   12,031,000   11,723,000 Effect of potential  common shares       1,483,000    1,136,000    1,553,000    1,124,000                    ————————————————— Diluted             13,350,000   13,055,000   13,584,000   12,847,000                    —————————————————